Lupin has received tentative approval from the Food and Drug Administration for sitagliptin and metformin hydrochloride tablets, 50 mg/500 mg and 50 mg/1000 mg, which is a generic of Merck Sharp & ...
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) approved JANUMET ® XR ...
Merck announced that the FDA has approved Janumet XR (sitagliptin/metformin HCl extended-release tablets) for the treatment of type 2 diabetes. Janumet XR is indicated as an adjunct to diet and ...
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- Merck today announced that the New Drug Application (NDA) for the Company's investigational extended-release formulation of JANUMET for type 2 diabetes has ...
New data presented at the American Diabetes Association 70 th Annual Scientific Sessions WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- New data were presented at the American Diabetes Association (ADA) ...
Janumet™ (MK-0431A) combines two OADs with complementary mechanisms of action to improve glycemic control, sitagliptin and metformin. The tablet was designed in order to be bioequivalent to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback